Press Releases

Investor Relations

Filter by Year

December 27, 2017

Acer Therapeutics Announces Partial Exercise of Over-allotment Option in Public Offering

NEWTON, MA – Dec. 27, 2017 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and ultra-rare diseases with critical unmet medical need, today announced that the underwriters of its previously announced public offering of common stock have partially exercised their over-allotment option […]

Read More
December 14, 2017

Acer Therapeutics Announces Closing of Underwritten Public Offering of Common Stock

NEWTON, MA – Dec. 14, 2017 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and ultra-rare diseases with critical unmet medical need, today announced the closing of the previously announced underwritten public offering of 916,667 shares of its common stock at a […]

Read More
December 12, 2017

Acer Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock

NEWTON, MA – Dec. 14, 2017 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and ultra-rare diseases with critical unmet medical need, today announced the closing of the previously announced underwritten public offering of 916,667 shares of its common stock at a […]

Read More
December 11, 2017

Acer Therapeutics Announces Proposed Underwritten Public Offering of Common Stock

NEWTON, MA – Dec. 11, 2017 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and ultra-rare diseases with critical unmet medical need, today announced that it intends to offer and sell shares of its common stock, subject to market and other conditions, […]

Read More
November 13, 2017

Acer Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update

Acer Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update Closed Merger and Concurrent $15.7M Financing Announced Positive Results from Pivotal Clinical Trial of EDSIVO™ (celiprolol) for Treatment of vEDS   CAMBRIDGE, MA – Nov. 13, 2017 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization […]

Read More
October 12, 2017

Acer Therapeutics Welcomes Two New Members to its Board of Directors

Mr. Jason Amello and Ms. Michelle Griffin Join the Board Acer Board Comprised of 7 Members   Cambridge, MA – October 12, 2017 Acer Therapeutics Inc., (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and ultra-rare diseases with critical unmet medical need, today announced the appointments […]

Read More
October 5, 2017

Acer Therapeutics Appoints Dr. William T. Andrews as Chief Medical Officer

Dr. Andrews’s Appointment Supports Acer’s Progression from Development to Potential Commercialization of Therapies   Cambridge, MA – October 5, 2017 Acer Therapeutics Inc., (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and ultra-rare diseases with critical unmet medical need, today announced the appointment of William T. […]

Read More
September 25, 2017

Acer Therapeutics Reports Positive Results From Pivotal Clinical Trial of EDSIVO™ (celiprolol) for Treatment of Vascular Ehlers-Danlos Syndrome

⦁ Company intends to file NDA for EDSIVO™ in first half of 2018     – September 25, 2017   Cambridge, MA – Acer Therapeutics Inc., (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and ultra-rare diseases with critical unmet medical need, today announced positive results from the […]

Read More
September 22, 2017

Acer Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference

CAMBRIDGE, MA, September 22, 2017 – Acer Therapeutics Inc., (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and ultra-rare diseases with critical unmet medical need, today announced that Chris Schelling, Chief Executive Officer and Founder, will provide a corporate overview at the Cantor Fitzgerald Global Healthcare […]

Read More
September 19, 2017

Acer Therapeutics and Opexa Therapeutics Close Merger and Financing

Acer Therapeutics and Opexa Therapeutics Close Merger and Financing -Merger to create a pre-NDA-stage, Nasdaq-listed, pharmaceutical company focused on the development and commercialization of therapies for serious rare diseases with critical unmet medical need- -Combined company, renamed Acer Therapeutics Inc., to commence trading on Nasdaq under the symbol “ACER” on September 21- -Concurrent financing of […]

Read More
QUICK
NAV